Nectar Lifesciences Extends Deadline for Slump Sale of Empty Hard Gelatin Capsule Business
Nectar Lifesciences Limited has announced an extension regarding the transfer of its Empty Hard Gelatin Capsule business. The company confirmed that the expected completion date for the slump sale has been mutually extended with the purchaser, Capnest Health Care Private Limited.The transaction involves Nectar Lifesciences Limited transferring the Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited on a slump sale basis.
Nectar Lifesciences Limited and Capnest Health Care Private Limited have mutually agreed to extend the expected completion date of this slump sale to on or before July 31, 2026.
The company previously disclosed the initial details of the slump sale in a letter dated December 20, 2025. All other relevant details pertaining to the slump sale transaction remain unchanged.
NECLIFE Stock Price Movement
Today, Nectar Lifesciences Limited shares edged higher, closing at ₹12.61, reflecting a gain of 0.40%. The stock found solid interest in session, posting a total traded volume of 416,188 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.